课题基金 / 基金详情

FDA-Drug Residue Cooperative Agreement Program (U18)

FDA-Drug Residue Cooperative Agreement Program (U18)
FDA-药物残留合作协议计划(U18)
批准号:
9770853
负责人:
William Gamble
金额:
$15.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-01 至 2021-06-30

项目摘要

项目成果

William Gamble的其他基金

相似基金

相关文献

中文摘要
翻译
爱荷华州农业和土地管理部 项目总结/摘要 药物残留预防计划(U18) 考虑到爱荷华州饲料制造业的巨大影响,通过 基于饲料/食品科学原理的药物残留预防教育 安全对于保护爱荷华州和全国乃至全世界的消费者至关重要。我们 有能力跟进残留物违规行为,并与生产商并肩工作, 解决方案是为供应链增加价值。 此外,总统在全国范围内对食品安全给予了高度重视, 美国国会通过了《食品安全现代化法案》(FSMA)。同样,在 我们发现爱荷华州对食品安全更感兴趣。 通过教育向团体提供信息是我们局工作的一大部分。 已确定与FDA药物残留合作协议计划取得成功。 在初期阶段,本局会重组现有职员的职务,让我们有时间评估是否有新的 需要工作人员在这方面提供协助。 我们将继续更新和教育我们的检查员关于预防药物残留的知识。我们 将制定药物残留预防材料,其中包括一项调查,我们的检查员将 在我们全年500+次的检查中分发。 我们的检查员将接受适当的培训,以便他们能够回答他们可能收到的任何问题。 我们会加强和提供现时已在使用的小册子, 畜牧业局以及创建我们自己的。我们将确保信息可以 以一种无法理解的方式传达给公众。 我们将在选定的展会上提供药物残留材料,并参与 邮件我们将记录培训研讨会的活动/网络研讨会,并将其发布到指定的 药物残留预防网页,以便它可以提供给任何人在任何时候。所记录的 研讨会沿着的信息小册子将在我们的网站上发布,以便 每个人都可以使用。该材料将在协议结束后继续提供。 该协议的目的是为了确保IDALS提高我们的药物残留 预防计划,以保护消费者暴露于药物残留的可食用产品, 食用动物这将通过教育外行和从业人员的风险, 药物残留并提供预防方法。对过去的侵犯行为采取后续行动将 也使未来的生产者/制造商获得知识,将有助于 防止侵权行为再次发生。IDALS将采取的这些措施将 大大提高了在爱荷华州和从爱荷华州出售的食品的质量。
英文摘要
Iowa Department of Agriculture & Land Stewardship (IDALS) Project Summary/Abstract Drug Residue Prevention Program (U18) Given the large impact of Iowa's feed manufacturing industry, providing information through education about the prevention of drug residue based on the scientific principles of feed/food safety is paramount to protecting Iowans and consumers throughout the nation and world. Our ability to follow up on residue violations and work side by side with the producer to find a solution is value added to the supply chain. Furthermore, the President has provided a significant level of focus on food safety nationally as has Congress with the passage of the Food Safety Modernization Act (FSMA). Similarly, within Iowa we have found an added interest in food safety. Speaking to groups to provide information through education is a large part of what our Bureau has identified to be successful with the FDA Drug Residue Cooperative Agreement Program. Initially the Bureau will restructure duties of existing staff to allow us time to evaluate if a new staff person is needed to assist in this area. We will continue to update and educate our inspectors about the prevention of drug resides. We will develop drug residue prevention material that will include a survey which our inspectors will hand out at all of our 500+ inspections throughout the year. Our inspectors will be properly trained so they can answer any questions that they may receive. We will enhance, and make available, the existing pamphlets that are already being used by the Animal Industry Bureau as well as create our own. We will make sure the information can be relayed to the public in a manner than can be understood. We will make available the drug residue materials at select fairs as well as being involved with mailings. We will record the event/webinar of a training seminar and post it onto a designated Drug Residue Prevention webpage so it can be available to anyone at any time. The recorded seminar along with the informational pamphlets will be posted on our website so they will be available to everyone. The material will continue to be available after the end of the agreement. The objective of this agreement is intended to ensure that IDALS enhances our drug residue prevention program to protect consumer exposure to drug residues in the edible products of food animals. This will be achieved by educating laypersons and practitioners of the risks of drug residues and providing them methods of prevention. Following up on past violations will also enable the future producers/manufacturers to gain knowledge that will assist in the prevention of the violation from occurring again. These steps IDALS will be taking will significantly enhance the quality of food sold in and from Iowa.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IA ERPS Cooperative Agreement
IA ERPS Cooperative Agreement
IDALS/FDA AFRPS Maintenance with PC Regulatory Activities
IDALS/FDA AFRPS Maintenance with PC Regulatory Activities
国内基金
海外基金
不同功能基团的电中性Drug-Free纳米颗粒的构建及克服肿瘤耐药的研究
  • 批准号:
    --
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2022
  • 负责人:
    杨胜彩
  • 依托单位:
Drug-ADR-Pathway复合网络构建及ADR分子机制研究
  • 批准号:
    61372188
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    陈秀杰
  • 依托单位:
Drug-pHLA对接指纹图谱库的构建及HLA介导SADR的预测方法研究
  • 批准号:
    61073135
  • 项目类别:
    面上项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2010
  • 负责人:
    梅虎
  • 依托单位:
新型药物传输系统drug-LDHs 复合纳米粒子的可控制备及其微结构对缓控释性能的调控
  • 批准号:
    20776012
  • 项目类别:
    面上项目
  • 资助金额:
    31.0万元
  • 批准年份:
    2007
  • 负责人:
    张慧
  • 依托单位: